NLS Pharmaceutics Reports Positive Mazindol Study Results
Ticker: NCEL · Form: 6-K · Filed: May 28, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | May 28, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: drug-development, clinical-trial-results, narcolepsy
TL;DR
NLS Pharma's Mazindol shows neuroprotective promise in narcolepsy rat study.
AI Summary
On May 28, 2024, NLS Pharmaceutics Ltd. announced positive results from its Study KO-874, which investigated the neuroprotective effects of Mazindol in a narcoleptic-like rat model. The study demonstrated that Mazindol exhibited neuroprotective properties, suggesting potential therapeutic benefits for narcolepsy.
Why It Matters
This study's positive findings on Mazindol's neuroprotective effects could lead to new treatment options for narcolepsy, a chronic neurological disorder.
Risk Assessment
Risk Level: medium — The company is reporting early-stage study results, and the actual therapeutic and commercial success of Mazindol is still uncertain.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Mazindol (drug) — Investigational compound
- Study KO-874 (study) — Clinical trial
- May 28, 2024 (date) — Announcement date
FAQ
What was the primary outcome of Study KO-874?
Study KO-874 demonstrated that Mazindol exhibited neuroprotective effects in a narcoleptic-like rat model.
What is the significance of Mazindol's neuroprotective effects?
The neuroprotective effects suggest potential therapeutic benefits for narcolepsy.
When did NLS Pharmaceutics Ltd. announce these results?
NLS Pharmaceutics Ltd. announced these results on May 28, 2024.
What type of animal model was used in Study KO-874?
A narcoleptic-like rat model was used in Study KO-874.
What form is this report filed under?
This report is filed as a Form 6-K.
Filing Stats: 270 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-05-28 09:13:57
Filing Documents
- ea0206912-6k_nlsphar.htm (6-K) — 11KB
- ea020691201ex99-1_nlsphar.htm (EX-99.1) — 16KB
- 0001213900-24-046825.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: May 28, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2